Jolanta Siller-Matula

Clinical practice of cangrelor use in Austrian ACS patients: a real-world multicenter registry

Introduction Cangrelor is the only available intravenous P2Y12 inhibitor and is primarily used in patients with acute coronary syndromes (ACS), especially those presenting with cardiac arrest without prior oral P2Y12 therapy. Despite guideline recommendations and evidence from the CHAMPION trials, real-world data on it...